What You Should Know:
A team of leading clinicians, engineers, and neuroscientists has made a groundbreaking discovery in the field of treatment-resistant depression. By analyzing the brain activity of patients undergoing deep brain stimulation (DBS), a promising therapy involving implanted electrodes that stimulate the brain, the researchers identified a unique pattern in brain activity that reflects the recovery process in patients with treatment-resistant depression.This pattern, known as
Read More
Biomarkers| Big Data| News, Analysis, Insights - HIT Consultant
ALZpath Secures Funding for Blood-Based Biomarker Testing for Alzheimer’s Disease Detection
What You Should Know:
- ALZpath, a developer of blood-based diagnostic biomarker testing for Alzheimer's disease detection receives funding from the Alzheimer’s Drug Discovery Foundation (ADDF)’s Diagnostics Accelerator to accelerate the clinical availability of ALZpathDx as a laboratory developed test (LDT).
- ALZpathDx is a novel, proprietary assay for blood-based measurement of phosphorylated tau at threonine 217 (pTau217), a highly accurate, diagnostic biomarker for
Read More
Philips & DoD Ink $10M Deal for AI-Wearable Disease Detection
What You Should Know:
The Department of Defense and Philips announced a $10M award to expand the readiness of our service members with the Rapid Assessment of Threat Exposure (RATE) AI wellness tool.The first group in this new cohort are theAir Force First Sergeants, who are responsible for overall squadron health and wellness.RATE is an AI algorithm, trained on clinical data from hospital-acquired infections to work with any off-the-shelf wearable to detect possible infection, acting
Read More
PsychoGenics Launches AI Platform to Revolutionize Drug Discovery
What You Should Know:
- PsychoGenics Inc., a provider of AI-enabled phenotypic drug discovery and preclinical CRO services launches eCube®, a novel pharmaco-electroencephalography (“pharmacoEEG”) platform.
The platform supports phenotypic drug discovery, which unlike traditional target-based drug discovery, can identify novel treatments with multiple targets.
How eCube Works
eCube measures drug-induced changes to EEG spectra data and utilizes machine learning classifiers trained
Read More
Genialis Raises $13M to Build Clinical Biomarkers that Predict Patient Response
What You Should Know:
Genialis, a computational precision medicine company unraveling complex biology to find new ways to address disease, today announced it raised more than $13 million in Series A financing to transform the way diseases are diagnosed and treatment decisions are made.Taiwania Capital and Debiopharm Innovation Fund co-led the round, with participation from previous investors First Star Ventures, Redalpine Venture Partners, and Pikas. Other new investors include P5 Health
Read More
Accenture: Data Collaboratives Hold Great Promise for Accelerated Healthcare Progress and Precision Medicine
What You Should Know:
- Accenture published Fast-Forwarding Healthcare through Data Collaboratives Report to discover how best health ecosystem players access data to fast-forward healthcare.
- Data generated by technical and scientific advances, like connected health devices, consumer health and medical-grade digital apps, individual multi-omics profiling data and the move to cloud storage, holds great promise for accelerated healthcare progress and precision medicine, and data
Read More
Protai Raises $20M to Build an Oncology Drug Discovery Pipeline
What You Should Know:
- Protai, a proteomics and AI-powered drug discovery startup revolutionizing the way new drugs are discovered, today announced a $12 million extension of its seed round, bringing the total amount to $20M.
- The round includes existing investors Grove Ventures and Pitango Healthcare and was joined by Copenhagen-based Maj Invest Equity Fund. The additional funding will be used to build Protai’s oncology drug discovery pipeline, expand data
Read More
Vysioneer & Pfizer Partner on AI-Powered Oncology Clinical Trials
What You Should Know:
- Vysioneer, a provider of applied AI for Oncology, today announced a data-sharing agreement with Pfizer, a global leader in pharmaceuticals. The agreement aims to lay the foundation for the application of AI in oncology clinical trials.
As part of the agreement, Vysioneer gains access to one of Pfizer's oncology clinical trial datasets to apply Vysioneer's advanced machine-learning techniques to facilitate the drug efficacy assessment process, thereby allowing Pfizer
Read More
FemTech: Joi Women’s Wellness Launches Nationwide
What You Should Know:
- Joi Women’s Wellness (Joi), a modern, femtech proactive approach to women’s health care, today announced the company’s official nationwide launch and availability of its hormone optimization and peptide therapy treatments, as well as the introduction of a new telehealth platform that provides a goals-based, customizable experience to help women own their health journey and manage the hormone and age–related changes to their bodies.
- Joi offers health coaching and
Read More
The New “Front Door” to Healthcare Can Only Open Fully with True Interoperability
Some people think of retail pharmacists as standing behind the counter bottling pills, answering insurance questions, or discussing side effects with a customer.
But the COVID pandemic fundamentally changed the role of the neighborhood pharmacist, from primarily dispensing medication to increasingly being the source of urgent and primary care for patients. With the successful administration of more than 300 million COVID vaccinations, an ongoing doctor shortage, and
Read More
